Drug* | Company | Indication | Number of trials analysed from FDA* approval package | Percentage of trials registered | Percentage of trials reported | Percentage of trials published | Percentage of trial results that are publicly available (reported or published) |
---|---|---|---|---|---|---|---|
Stribild | Gilead | HIV | 34 | 24 | 9 | 21 | 21 |
Aubagio | Sanofi | Multiple sclerosis | 32 | 34 | 19 | 16 | 22 |
Elelyso | Pfizer & Protalix | Gaucher disease | 5 | 100 | 20 | 40 | 40 |
Zaltrap | Sanofi | Colorectal cancer | 30 | 40 | 30 | 37 | 40 |
Stivarga | Bayer | Colorectal cancer | 12 | 75 | 17 | 42 | 42 |
Eliquis | BMS | Anticoagulant | 39 | 26 | 10 | 44 | 44 |
Zioptan | Merck & Santen | Eye pressure, glaucoma | 16 | 25 | 13 | 44 | 44 |
Xeljanz | Pfizer | Rheumatoid arthritis | 34 | 82 | 53 | 56 | 65 |
Bosulif | Pfizer | Leukaemia | 17 | 100 | 24 | 71 | 71 |
Perjeta | Genentech/Roche | Breast cancer | 12 | 50 | 8 | 75 | 75 |
Signifor | Novartis | Cushing’s disease | 17 | 29 | 12 | 82 | 82 |
Erivedge | Genentech/Roche | Basal cell carcinoma | 12 | 83 | 25 | 83 | 83 |
Inlyta | Pfizer | Renal cell carcinoma | 28 | 61 | 46 | 100 | 100 |
Sirturo | Janssen (J&J) | Tuberculosis | 14 | 57 | 21 | 93 | 100 |
MenHibrix | GSK | Meningitis vaccine, children | 16 | 100 | 100 | 100 | 100 |
Median | 17 | 57 | 20 | 56 | 65 | ||
IQR | 13–31 | 32–83 | 12–28 | 41–83 | 41–83 |
*For a list of the active ingredients for these drugs (see online supplementary appendix 2).